Corrigendum: A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children’s Oncology Group Study ANBL0931

Özkaynak, M. Fevzi; Gilman, Andrew L.; London, Wendy B.; Naranjo, Arlene; Diccianni, Mitchell B.; Tenney, Sheena C.; Smith, M. Charles; Messer, Karen; Seeger, Robert C.; Reynolds, C. Patrick; Smith, L. Mary; Shulkin, Barry L.; Parisi, Marguerite T.; Maris, John M.; Park, Julie R.; Sondel, Paul M.; Yu, Alice L.

doi:10.3389/fimmu.2018.01641

Cited by 5 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…18 ), a diasylganglioside found on a subset of NB cells, proved useful in the setting of minimal residual disease, yet showed little effect on the growth of bulky tumors in the relapsed and refractory setting. [19][20][21][22][23][24][25][26] However, the combination of dinutuximab with chemotherapy resulted in a 47% response rate, with complete and partial responses seen in relapsed/refractory patients with bulky metastatic disease 27 . Furthermore, the combination of chemotherapy and a similar monocloncal anti-GD2 antibody in newly diagnosed high-risk NB patients has shown thus far response rates as high as 80%.…”

Section: Introductionmentioning

confidence: 99%

Ex vivo expanded patient-derived γδ T-cell immunotherapy enhances neuroblastoma tumor regression in a murine model

et al. 2019

View full text Add to dashboard Cite

An effective therapy regimen for relapsed/refractory high-risk neuroblastoma (NB) includes the anti-GD2 monoclonal antibody, dinutuximab, in combination with temozolomide and irinotecan, supporting a role for chemo-immunotherapy in NB. γδ T cells are an attractive anti-tumor immunotherapy because of their direct cytotoxic activity mediated through cell surface receptors NKG2D and CD16. NKG2D facilitates the innate recognition of stress-induced ligands whereas CD16 recognizes antibody bound to tumors and activates mechanisms of antibody-dependent cellular cytotoxicity (ADCC). This study demonstrates an efficient method for expanding and storing γδ T cells from NB patient-derived apheresis products at clinically relevant amounts. The expanded patient-derived γδ T cells were cytotoxic against the K562 cell line and multiple NB cell lines. Combining γδ T cells with dinutuximab led to a 30% increase in tumor cell lysis compared to γδ T cells alone. Furthermore, low-dose temozolomide in combination with expanded γδ T cells and dinutuximab resulted in increased IFNγ secretion and increased γδ T-cell surface expression of FasL and CD107a. IMR5 NB cell line xenografts established subcutaneously in NSG mice were treated with a regimen of dinutuximab, temozolomide, and γδ T cells. This combination caused targeted killing of NB xenografts in vivo, reducing tumor burden and prolonging survival. These data support the continued preclinical testing of dinutuximab and temozolomide in conjunction with γδ T-cell immunotherapy for patients with recurrent/refractory NB.

show abstract

Section: Introductionmentioning

confidence: 99%

Ex vivo expanded patient-derived γδ T-cell immunotherapy enhances neuroblastoma tumor regression in a murine model

et al. 2019

View full text Add to dashboard Cite

show abstract

“…The ADCC effect of anti-GD2 monoclonal antibody on NB cells is associated with the Fc receptor (FcR) on killer cells, which combines with the Fc fragment of the anti-GD2 monoclonal antibody, activating ADCC and inducing the apoptosis of NB (26). A number of studies have used anti-GD2 monoclonal antibody combined with granulocyte-macrophage colony stimulating factor (GM-CSF) or interleukin-2 (IL-2), and have demonstrated that combination therapy exerts stronger effects compared with using anti-GD2 monoclonal antibody alone (27–29). This indicates that an increase in the number or activity of killer cells is a key factor in enhancing the efficacy of anti-GD2 monoclonal antibody.…”

Section: Introductionmentioning

confidence: 99%

Cytokine‑induced killer cells/natural killer cells combined with anti‑GD2 monoclonal antibody increase cell death rate in neuroblastoma SK‑N‑SH cells

Zhang

Xiong

et al. 2019

Oncol Lett

View full text Add to dashboard Cite

show abstract

Anti-GD2 antibody-containing immunotherapy postconsolidation therapy for people with high-risk neuroblastoma treated with autologous haematopoietic stem cell transplantation

Peinemann

Dalen

Enk

et al. 2019

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

show abstract

Corrigendum: A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children’s Oncology Group Study ANBL0931

Cited by 5 publications

References 0 publications

Ex vivo expanded patient-derived γδ T-cell immunotherapy enhances neuroblastoma tumor regression in a murine model

Ex vivo expanded patient-derived γδ T-cell immunotherapy enhances neuroblastoma tumor regression in a murine model

Cytokine‑induced killer cells/natural killer cells combined with anti‑GD2 monoclonal antibody increase cell death rate in neuroblastoma SK‑N‑SH cells

Anti-GD2 antibody-containing immunotherapy postconsolidation therapy for people with high-risk neuroblastoma treated with autologous haematopoietic stem cell transplantation

Contact Info

Product

Resources

About